Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdala

Journal of Neurophysiology

Volumn 112, Issue 4, 2014, Pages 890-902

  Martin, Brandon S ^a,b   Corbin, Joshua G ^a   Huntsman, Molly M ^c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Amygdala; Fragile X syndrome; GABA; Tonic inhibition

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; GABOXADOL; 3-(5-METHYLISOXAZOL-3-YL)-6-((1-METHYL-1,2,3-TRIAZOL-4-YL)METHYLOXY)-1,2,4-TRIAZOLO(3,4-A)PHTHALAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR; FMR1 PROTEIN, MOUSE; FRAGILE X MENTAL RETARDATION PROTEIN; ISOXAZOLE DERIVATIVE; PHTHALAZINE DERIVATIVE; PROTEIN SUBUNIT; PYRIDAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

4 AMINOBUTYRIC ACID RELEASE; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL AMYGDALA; CELL SIZE; CONDUCTANCE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EVOKED RESPONSE; FRAGILE X SYNDROME; GABAERGIC TRANSMISSION; IMMUNOHISTOCHEMISTRY; INTRACELLULAR RECORDING; MOUSE; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPSE; SYNAPTIC EFFICACY; SYNAPTIC TRANSMISSION; ANIMAL; CYTOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; FEEDBACK SYSTEM; GENETICS; INHIBITORY POSTSYNAPTIC POTENTIAL; METABOLISM; PHYSIOLOGY; PROTEIN SUBUNIT;

AMYGDALA; ANIMALS; EXCITATORY POSTSYNAPTIC POTENTIALS; FEEDBACK, PHYSIOLOGICAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GABA-A RECEPTOR AGONISTS; GABA-A RECEPTOR ANTAGONISTS; GABAERGIC NEURONS; INHIBITORY POSTSYNAPTIC POTENTIALS; ISOXAZOLES; MICE; PHTHALAZINES; PROTEIN SUBUNITS; PYRIDAZINES; RECEPTORS, GABA-A; SYNAPSES; TRIAZOLES;

EID: 84906078573     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00597.2013     Document Type: Article

References (63)

1. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59: 167-171, 2010.
2. Areceptors mediate IPSPs elicited by dendrite-preferring cells in rat neocortex. Cereb Cortex 18: 1260-1271, 2008.
3. Areceptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacol Ther 125: 11-26, 2010.
4. Aalpha5-selective compound L-655,708. Drug Metab Dispos 34: 887-893, 2006.
5. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370-377, 2004.
6. Areceptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. J Neurophysiol 98: 2244-2254, 2007.
7. Brager DH, Johnston D. Channelopathies and dendritic dysfunction in fragile X syndrome. Brain Res Bull 103: 11-17, 2014.
8. Areceptors: their function in the CNS and implications for disease. Neuron 73: 23-34, 2012.
9. Areceptors. Br J Pharmacol 136: 965-974, 2002.
10. Areceptors form clusters at GABAergic synapses in hippocampal cultures. Neuroreport 13: 2355-2358, 2002.
11. Cruikshank SJ, Lewis TJ, Connors BW. Synaptic basis for intense thalamocortical activation of feedforward inhibitory cells in neocortex. Nat Neurosci 10: 462-468, 2007.
12. Curia G, Papouin T, Séguéla P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 19: 1515-1520, 2009.
13. Areceptor in fragile X syndrome. Brain Res 1121: 238-245, 2006.
14. Ehrlich I, Humeau Y, Grenier F, Ciocchi S, Herry C, Lüthi A. Amygdala inhibitory circuits and the control of fear memory. Neuron 62: 757-771, 2009.
15. Areceptor expression in the seizure-prone fragile X mouse. Neurosci Lett 377: 141-146, 2005.
16. Areceptors. Nat Rev Neurosci 6: 215-229, 2005.
17. A-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol 359: 154-194, 1995.
18. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG, Warren ST. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67: 1047-1058, 1991.
19. Gabernet L, Jadhav SP, Feldman DE, Carandini M, Scanziani M. Somatosensory integration controlled by dynamic thalamocortical feed-forward inhibition. Neuron 48: 315-327, 2005.
20. Areceptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis 21: 346-357, 2006.
21. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 17: 103-111, 2007.
22. Gibson JR, Bartley AF, Hays SA, Huber KM. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol 100: 2615-2626, 2008.
23. Glykys J, Mody I. The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J Physiol 582: 1163-1178, 2007.
24. Gonçalves JT, Anstey JE, Golshani P, Portera-Cailliau C. Circuit level defects in the developing neocortex of Fragile X mice. Nat Neurosci 16: 903-909, 2013.
25. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M. Advances in the treatment of fragile X syndrome. Pediatrics 123: 378-390, 2009.
26. Hays SA, Huber KM, Gibson JR. Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. J Neurosci 31: 14223-14234, 2011.
27. He CX, Portera-Cailliau C. The trouble with spines in fragile X syndrome: density, maturity and plasticity. Neuroscience 251: 120-128, 2013.
28. Areceptor-mediated inhibition are enhanced during thalamic development. J Neurophysiol 83: 350-358, 2000.
29. Isaacson JS, Scanziani M. How inhibition shapes cortical activity. Neuron 72: 231-243, 2011.
30. König P, Engel AK, Singer W. Integrator or coincidence detector? The role of the cortical neuron revisited. Trends Neurosci 19: 130-137, 1996.
31. Krettek JE, Price JL. A description of the amygdaloid complex in the rat and cat with observations on intra-amygdaloid axonal connections. J Comp Neurol 178: 255-280, 1978.
32. Krook-Magnuson EI, Li P, Paluszkiewicz SM, Huntsman MM. Tonically active inhibition selectively controls feedforward circuits in mouse barrel cortex. J Neurophysiol 100: 932-944, 2008.
33. Lloyd DP. Facilitation and inhibition of spinal motoneurons. J Neurophysiol 9: 421-438, 1946.
34. Manko M, Bienvenu TC, Dalezios Y, Capogna M. Neurogliaform cells of amygdala: a source of slow phasic inhibition in the basolateral complex. J Physiol 590: 5611-5627, 2012.
35. Markram K, Markram H. The intense world theory-a unifying theory of the neurobiology of autism. Front Hum Neurosci 4: 224, 2010.
36. Areceptors. J Neurosci 32: 8611-8619, 2012.
37. Areceptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J Neurosci 30: 5269-5282, 2010.
38. McDonald AJ, Mascagni F. Cortico-cortical and cortico-amygdaloid projections of the rat occipital cortex: a Phaseolus vulgaris leucoagglutinin study. Neuroscience 71: 37-54, 1996.
39. McDonald AJ, Mascagni F, Mania I, Rainnie DG. Evidence for a perisomatic innervation of parvalbumin-containing interneurons by individual pyramidal cells in the basolateral amygdala. Brain Res 1035: 32-40, 2005.
40. McNaughton BL, Barnes CA, Andersen P. Synaptic efficacy and EPSP summation in granule cells of rat fascia dentata studied in vitro. J Neurophysiol 46: 952-966, 1981.
41. Mitchell SJ, Silver RA. Shunting inhibition modulates neuronal gain during synaptic excitation. Neuron 38: 433-445, 2003.
42. Muller JF, Mascagni F, McDonald AJ. Postsynaptic targets of somatostatincontaining interneurons in the rat basolateral amygdala. J Comp Neurol 500: 513-529, 2007.
43. Nicoll A, Larkman A, Blakemore C. Modulation of EPSP shape and efficacy by intrinsic membrane conductances in rat neocortical pyramidal neurons in vitro. J Physiol 468: 693-710, 1993.
44. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 30: 9929-9938, 2010.
45. Ottersen OP. Connections of the amygdala of the rat. IV. Corticoamygdaloid and intraamygdaloid connections as studied with axonal transport of horseradish peroxidase. J Comp Neurol 205: 30-48, 1982.
46. Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci 33: 349-364, 2011a.
47. Paluszkiewicz SM, Olmos-Serrano JL, Corbin JG, Huntsman MM. Impaired inhibitory control of cortical synchronization in fragile X syndrome. J Neurophysiol 106: 2264-2272, 2011b.
48. Areceptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101: 815-850, 2000.
49. Poo C, Isaacson JS. Odor representations in olfactory cortex: "sparse" coding, global inhibition, and oscillations. Neuron 62: 850-861, 2009.
50. Postlethwaite M, Hennig MH, Steinert JR, Graham BP, Forsythe ID. Acceleration of AMPA receptor kinetics underlies temperature-dependent changes in synaptic strength at the rat calyx of Held. J Physiol 579: 69-84, 2007.
51. Pouille F, Scanziani M. Enforcement of temporal fidelity in pyramidal cells by somatic feed-forward inhibition. Science 293: 1159-1163, 2001.
52. 3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha5 subunit. Neuropharmacology 35: 1331-1335, 1996.
53. Sah P, Faber ESL, Lopez De Armentia M, Power J. The amygdaloid complex: anatomy and physiology. Physiol Rev 83: 803-834, 2003.
54. Areceptors: modulating gain and maintaining the tone. Trends Neurosci 27: 262-269, 2004.
55. Smith Y, Paré D. Intra-amygdaloid projections of the lateral nucleus in the cat: PHA-L anterograde labeling combined with postembedding GABA and glutamate immunocytochemistry. J Comp Neurol 342: 232-248, 1994.
56. Areceptors: functional selectivity for extrasynaptic receptors is dependent on the absence of gamma2. J Pharmacol Exp Ther 316: 1351-1359, 2006.
57. Stuart G, Spruston N. Determinants of voltage attenuation in neocortical pyramidal neuron dendrites. J Neurosci 18: 3501-3510, 1998.
58. Testa-Silva G, Loebel A, Giugliano M, de Kock CP, Mansvelder HD, Meredith RM. Hyperconnectivity and slow synapses during early development of medial prefrontal cortex in a mouse model for mental retardation and autism. Cereb Cortex 22: 1333-1342, 2012.
59. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-914, 1991.
60. Vislay RL, Martin BS, Olmos-Serrano JL, Kratovac S, Nelson DL, Corbin JG, Huntsman MM. Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in fragile X syndrome. J Neurosci 33: 7548-7558, 2013.
61. Wehr M, Zador AM. Balanced inhibition underlies tuning and sharpens spike timing in auditory cortex. Nature 426: 442-446, 2003.
62. Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 30: 5724-5729, 2010.
63. Zhang L, He J, Jugloff DG, Eubanks JH. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus 18: 294-309, 2008.